In his comments on INDIRAB® reaching 10 million doses mark Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech International said Bharat Biotech’s vaccine manufacturing methods are best suited to meet growing demand for novel, cost effective vaccines. We believe that our 3rd generation rabies Vero cell based vaccine produced using chromatographically purified manufacturing process offers not just lower costs but also a highly purified vaccine with minimal side effects.
Bharat Biotech continues to make new investments to expand its production facilities at its Hyderabad plant to meet the rising demand for rabies vaccine both in the domestic and international markets. The capacity expansion will also help meet the requirements from new vaccine development programs the company has in the pipeline.
INDIRAB® is one of the first Chromatographically Purified Vero Cell Rabies Vaccine in the world. It was developed from virus strains obtained from CDC (Centers for Disease Control & Prevention), Atlanta, USA. Chromatographically Purified INDIRAB® is free from inapparent viruses and adventitious agents capable of causing tumors. With superior technology, Chromatographically Purified INDIRAB® is safe with no chance of egg protein allergy, antibiotic allergy and bird flu transmission, seen with chick and duck embryo rabies vaccines. INDIRAB was launched in the year 2006 and is a market leader today with supplies to several state governments within India both for intra muscular and intra dermal administrations.
Rabies disease is lethal encephalitis caused by rabies virus belonging to genus lyssavirus and transmitted from animals to humans via bite wound, scratch wound, or licking of mucous membranes. It is preventable by timely administration of post-exposure prophylaxis (PEP) consisting of five doses of rabies vaccine combined, in the most severe cases of exposures, with anti-rabies immunoglobulin (RIG).
The global market for anti rabies vaccine is estimated at over 50 million doses, annually.
About Bharat Biotech International Ltd Bharat Biotech International Limited, Hyderabad, India, is a multidimensional biotechnology company specializing in product-oriented research, development and manufacturing of vaccines and biotherapeutics. Bharat Biotech was established in the year 1996, is engaged in developing next-generation vaccines and biotherapeutics through innovative and collaborative research. Bharat Biotech is one of the first bio-pharma facilities in India to be audited and approved by Korean Food & Drugs Administration (KFDA). Bharat Biotech is also a WHO prequalified manufacturer of Hepatitis-B vaccines for supply to UNICEF and global procurement agencies.
Bharat Biotech sprawls over a picturesque campus at Genome Valley, Hyderabad, built with an investment of over USD 100 million, the facility’s Manufacturing, Control Procedures and Protocols, conform to the stringent standards laid down by internationally recognized institutions such as USFDA, UKMCA and WHO. Bharat has set new benchmarks in Innovation and Quality that epitomizes the tremendous progress of Indian biotechnology in the global arena. Bharat Biotech is the largest primary manufacturer of Vi Capsular Polysaccharide Typhoid vaccine, TYPBAR™. Bharat Biotech has commercialized India’s first recombinant Epidermal Growth Factor, REGEN-D® to combat diabetic foot ulcers, burns. Bharat Biotech’s INDIRAB® (anti-rabies vaccine) is a market leader in protection against rabies infections from dog bites. Bharat Biotech is a world leader in Hepatitis B vaccines as the first Company in the world to manufacture REVAC-B MCF®, a cesium chloride free and Thiomersol free hepatitis B vaccine. Bharat Biotech has a strong pipeline of vaccines and therapeutics to combat Malaria, Rotavirus, Staph aureus (MRSA) and Japanese Encephalitis infections.
Important information about forward-looking statements Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the prospectus.
Media contact for Bharat Biotech International
Sheela / Muralidharan enRight PR enRight@enrigtpr.com www.enrightpr.com
